Community-onset Escherichia coli and Klebsiella pneumoniae bacteremia: influence of health care exposure on antimicrobial susceptibility

Diagnostic Microbiology and Infectious Disease
Hsin-Yun SunYee-Chun Chen

Abstract

Three hundred forty-one case patients with Escherichia coli bacteremia and 173 case patients with Klebsiella pneumoniae bacteremia were enrolled in this prospective observational study to compare the clinical manifestations of infections in the 2 organisms and to delineate the change in resistance of isolates after health care exposure. Liver abscess, primary bacteremia, and respiratory tract infection were more commonly seen in patients with K. pneumoniae bacteremia, whereas urinary tract infection was more common in those with E. coli bacteremia. The influence of prior hospitalization on resistance of E. coli to some antibiotics could be observed for as long as 6 months after discharge. Patients undergoing procedures in the outpatient setting and nursing home residents also had infections with more resistant E. coli strains than those without hospital exposure within the previous year. However, no difference in resistance was observed in K. pneumoniae isolates from patients in different clinical settings.

References

Mar 1, 1994·Antimicrobial Agents and Chemotherapy·E J Vollaard, H A Clasener
Nov 18, 1997·Epidemiology and Infection·L M TangC M Chen
Jun 24, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J H WangH H Lin
Mar 20, 2001·Thorax·UNKNOWN British Thoracic Society Standards of Care Committee
Mar 19, 2002·Emerging Infectious Diseases·Wen-Chien KoVictor L Yu
May 11, 2002·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Karin E ByersBarry M Farr
May 17, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yardena Siegman-IgraMichael Giladi
Jun 28, 2003·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Paul A TambyahGamini Kumarasinghe
Mar 11, 2005·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Olivier LesensDaniel Christmann

❮ Previous
Next ❯

Citations

May 25, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·T-Y ChuangP-R Hsueh
Oct 11, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M N Al-HasanL M Baddour
Feb 5, 2011·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Chia-Jung HsiehKao-Pin Hwang
Feb 20, 2014·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Ling-Fu HuangChin-Lu Chang
Jan 22, 2014·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Tzu-Yi ChuangPo-Ren Hsueh
Oct 7, 2009·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Jonas MarschallDavid K Warren
Nov 10, 2017·The Korean Journal of Internal Medicine·Miri HyunHyun Ah Kim
Aug 29, 2012·Journal of Food Science·Ugur Gogus

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.